Immunotherapy for advanced NSCLC has been advancing; immunohistochemistry for PD‐L1 expression allows for an initial assessment of whether a patient can benefit from PD‐1/PD‐L1 therapy. Here, PDCD1 is linked to non-small cell lung carcinoma.